Recurrence dynamics does not depend on the recurrence site

Romano Demicheli, Elia Biganzoli, Patrizia Boracchi, Marco Greco, Michael W Retsky, Romano Demicheli, Elia Biganzoli, Patrizia Boracchi, Marco Greco, Michael W Retsky

Abstract

Introduction: The dynamics of breast cancer recurrence and death, indicating a bimodal hazard rate pattern, has been confirmed in various databases. A few explanations have been suggested to help interpret this finding, assuming that each peak is generated by clustering of similar recurrences and different peaks result from distinct categories of recurrence.

Methods: The recurrence dynamics was analysed in a series of 1526 patients undergoing conservative surgery at the National Cancer Institute of Milan, Italy, for whom the site of first recurrence was recorded. The study was focused on the first clinically relevant event occurring during the follow up (ie, local recurrence, distant metastasis, contralateral breast cancer, second primary tumour), the dynamics of which was studied by estimating the specific hazard rate.

Results: The hazard rate for any recurrence (including both local and distant disease relapses) displayed a bimodal pattern with a first surge peaking at about 24 months and a second peak at almost 60 months. The same pattern was observed when the whole recurrence risk was split into the risk of local recurrence and the risk of distant metastasis. However, the hazard rate curves for both contralateral breast tumours and second primary tumours revealed a uniform course at an almost constant level. When patients with distant metastases were grouped by site of recurrence (soft tissue, bone, lung or liver or central nervous system), the corresponding hazard rate curves displayed the typical bimodal pattern with a first peak at about 24 months and a later peak at about 60 months.

Conclusions: The bimodal dynamics for early stage breast cancer recurrence is again confirmed, providing support to the proposed tumour-dormancy-based model. The recurrence dynamics does not depend on the site of metastasis indicating that the timing of recurrences is generated by factors influencing the metastatic development regardless of the seeded organ. This finding supports the view that the disease course after surgical removal of the primary tumour follows a common pathway with well-defined steps and that the recurrence risk pattern results from inherent features of the metastasis development process, which are apparently attributable to tumour cells.

Figures

Figure 1
Figure 1
Hazard rate estimates for selected events in 1526 patients undergoing conservative surgery. Each point represents the measure of the hazard rate of the given event within a three-month interval. The smoothed curve was obtained by a Kernel-like smoothing procedure. (a) Hazard rate for any recurrence (including both local and distant disease relapses). (b) The hazard rate for recurrence is split into its components: local recurrence (red line) and distant metastasis (blue line). (c) Hazard rate for contralateral breast cancer. (d) Hazard rate for second primary cancer.
Figure 2
Figure 2
Hazard rate for selected events in 1526 patients undergoing conservative surgery. The same events as in Figure 1 were analysed by a formal flexible regression modelling strategy considering B-spline bases with degrees of freedom ranging from 4 to 10 and selecting the best models according to the Akaike Information Criterion. Vertical lines represent point-wise confidence interval for the model estimated hazards, according to standard asymptotic theory.
Figure 3
Figure 3
Hazard rate for distant metastasis in different sites. Distant metastases were categorised as bone, viscera and soft tissue recurrences. Soft tissue metastases also included the supra-clavicular lymph node recurrences. Because of the limited number of events to a single visceral site, recurrences to lung, liver or CNS were merged to obtain a more suitable collection of cases, representative of the visceral recurrence. Vertical lines represent point-wise confidence intervals for the model estimated hazards, according to standard asymptotic theory.

References

    1. Demicheli R, Valagussa P, Foroni R, Bonadonna G. Mean relapse rate per year (MRR/Y) suggests different biological conditions of breast cancer micrometastases at the time of primary local-regional treatment. Proc Am Soc Clin Oncol. 1993;12:119.
    1. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumour dormancy. Breast Cancer Res Treat. 1996;41:177–185. doi: 10.1007/BF01807163.
    1. Demicheli R, Bonadonna G, Hrushesky WJM, Retsky MW, Valagussa P. Menopausal status dependence of the timing of breast cancer recurrence following primary tumour surgical removal. Breast Cancer Res. 2004;6:R689–696. doi: 10.1186/bcr937.
    1. Baum M, Badwe RA. Does surgery influence the natural history of breast cancer? In: Johnson H Jr, editor. Breast Cancer: Controversies in Management. Armonk, NY: Futura Publishing Company Inc; 1994. pp. 61–69.
    1. Fortin A, Larochelle M, Laverdiere J, Lavertu S, Tremblay D. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol. 1999;17:101–109.
    1. Gasparini G, Biganzoli E, Bonoldi E, Morabito A, Fanelli M, Boracchi P. Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2001;65:71–75. doi: 10.1023/A:1006476401801.
    1. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005;89:173–178. doi: 10.1007/s10549-004-1722-0.
    1. Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, Valagussa P, Bonadonna G. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumour dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005;16:1449–1457. doi: 10.1093/annonc/mdi280.
    1. Jerez JM, Franci L, Alba E, Llombart-Cussiac A, Lluch A, Ribelles N, Munarriz B, Martin M. Improvements of breast cancer prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat. 2005;94:265–272. doi: 10.1007/s10549-005-9013-y.
    1. Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, Berrino F. Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer. 1991;27:981–984.
    1. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91:80–85. doi: 10.1093/jnci/91.1.80.
    1. Yakovlev AY, Tsodikov AD, Boucher K, Kerber R. The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer. 1999;85:1789–1798. doi: 10.1002/(SICI)1097-0142(19990415)85:8<1789::AID-CNCR20>;2-Q.
    1. Gao F, Tan SB, Machin D, Wong NS. Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Res. 2007;9:R21. doi: 10.1186/bcr1658.
    1. Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G. Proposal for a new model of breast cancer metastatic development. Ann Oncol. 1997;8:1075–1080. doi: 10.1023/A:1008263116022.
    1. Retsky MW, Demicheli R, Swartzendruber DE, Bame PD, Wardwell RH, Bonadonna G, Speer JF, Valagussa P. Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat. 1997;45:193–202. doi: 10.1023/A:1005849301420.
    1. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A, Zucali R. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305:6–11.
    1. Kamby C, Rose C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, Andersen KW, Zedeler K. Stage and pattern of metastases in patients with breast cancer. Eur J Cancer Clin Oncol. 1987;23:1925–1934. doi: 10.1016/0277-5379(87)90061-7.
    1. Ramlau-Hansen H. Smoothing counting process intensities by means of Kernel functions. Ann Statistics. 1983;11:453–466. doi: 10.1214/aos/1176346152.
    1. Boracchi P, Biganzoli E, Marubini E. Joint modelling of cause specific hazard functions with cubic splines: an application to a large series of breast cancer patients. Comput Statist Data Anal. 2003;42:243–262. doi: 10.1016/S0167-9473(02)00122-6.
    1. Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Amer Statist Assoc. 1992;87:942–951. doi: 10.2307/2290630.
    1. Dawson PJ, Maloney T, Gimotty P, Juneau P, Ownby H, Wolman SR. Bilateral breast cancer: one disease or two? Breast Cancer Res Treat. 1991;19:233–244. doi: 10.1007/BF01961160.
    1. Broet P, de la Rochefordiere a, Scholl SM, Fourquet A, Mosseri M, Durand JC, Pouillart P, Asselain B. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13:1578–1583.
    1. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, Saffer E, Wickerham L, Lerner H, Glass A, Shibata H, Deckers P, Ketcham A, Oishi R, Russel I. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665–673.
    1. Recht A, Silen W, Connolly J, Gelman RS, Rose MA, Silver B, Harris JR. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1988;15:255–261. doi: 10.1016/S0360-3016(98)90002-5.
    1. Hafty BG, Fisher D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21:293–298.
    1. Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC, Feig BW, Kuerer HM, Ross MI, Singletary SE, McNeese MD, Strom EA, Hunt KK. Classifying local disease recurrences after breast conservation therapy based on location and histology. New primary tumours have more favourable outcomes than true local disease recurrences. Cancer. 2002;95:2059–2067. doi: 10.1002/cncr.10952.
    1. Komoike Y, Akiyama F, Iino Y, Ikeda T, Tanaka-Akashi S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T, Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M, Tsukuma H, Inaji H. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer. 2005;12:104–111. doi: 10.2325/jbcs.12.104.
    1. Smith TE, Lee D, Turner BC, Carter D, Haffty BG. True recurrence vs. new primary ipsilateral breast tumour relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48:1281–1289.
    1. Voogd AC, van Oost FJ, Rutgers EJT, Elkhuizen PHM, van Geel AN, Scheijmans LJEE, Sangen MJC van der, Botke G, Hoekstra CJ, Jobsen JJ, Velde CJH van de, von Meyenfeldt MF, Tabak JM, Peterse JL, Vijver MJ van de, Coeberg JWW, van Tienhoven G, for the Dutch Study Group on Local Recurrence after Breast Conservation (BORST Group) Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer. 2005;41:2637–2644. doi: 10.1016/j.ejca.2005.04.040.
    1. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biologic properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–340. doi: 10.1038/nrc2375.
    1. Husemann Y, Geigl JB, Shubert F, Musiani P, Meyer M, Burghert E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68. doi: 10.1016/j.ccr.2007.12.003.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe